Analyst firms · H.C. Wainwright · BHVN
H.C. Wainwright BHVN price target and rating history
Biohaven Ltd. (BHVN) · Health Care
H.C. Wainwright rates Biohaven Ltd. (BHVN) Neutral with a $11 price target, as of its latest action on Dec 3, 2025. It has published 4 rating actions on BHVN since July 2021, including 0 upgrades and 1 downgrade. Across 6 firms with a BHVN price target in the last 12 months, the median target is $15. H.C. Wainwright's $11 is 27% below that.
- Current rating
- Neutral
- Price target
- $11
- Median target, all firms
- $15
- Actions on BHVN
- 4
H.C. Wainwright price target on BHVN
Every H.C. Wainwright rating on BHVN
- Dec 3, 2025
- Dec 22, 2023
- Oct 6, 2021
- Jul 8, 2021
How other firms rate BHVN
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| RBC Capital Markets | Sector Perform | $19 | Sep 8, 2026 |
| BofA Securities | Underperform | $11 | Jun 29, 2026 |
| Canaccord Genuity | Buy | $21 | Apr 13, 2026 |
| Goldman Sachs | Buy | $23 | Feb 6, 2026 |
| H.C. Wainwright | Neutral | $11 | Dec 3, 2025 |
| UBS | Neutral | $11 | Nov 26, 2025 |
Questions about H.C. Wainwright and BHVN
- What is H.C. Wainwright's price target for BHVN?
- H.C. Wainwright's latest stated price target for Biohaven Ltd. (BHVN) is $11, from its action on Dec 3, 2025.
- What is H.C. Wainwright's rating on BHVN?
- H.C. Wainwright rates BHVN Neutral, a neutral rating, as of Dec 3, 2025.
- When did H.C. Wainwright last change its view on BHVN?
- On Dec 3, 2025, H.C. Wainwright downgrades to Neutral from Buy, price target $11.
- How does H.C. Wainwright's BHVN target compare with other analysts?
- Across 6 firms with a BHVN price target in the last 12 months, the median target is $15. H.C. Wainwright's $11 is 27% below that.
More BHVN rating histories
All H.C. Wainwright ratingsBHVN news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.